Management of Elevated Albumin to Creatinine Ratio

Classification and Management

The American Diabetes Association recommends classifying albuminuria into three categories: A1 (Normal to Mildly Increased): uACR <30 mg/g, A2 (Moderately Increased): uACR 30-299 mg/g, and A3 (Severely Increased): uACR ≥300 mg/g 3
For patients with elevated albumin to creatinine ratio, the cornerstone of management is treatment with an ACE inhibitor or angiotensin receptor blocker (ARB), along with optimization of blood pressure and glucose control, as recommended by the American Diabetes Association 1, 2

For A1 (Normal to Mildly Increased), monitor annually in patients with diabetes, and ACE inhibitors or ARBs are NOT recommended for primary prevention in normotensive patients with normal UACR, as suggested by the American Diabetes Association 1, 2
For A2 (Moderately Increased), initiate ACE inhibitor or ARB therapy, optimize blood pressure control (target <140/90 mmHg), and optimize glycemic control in diabetic patients, as recommended by the American Diabetes Association and the European Society of Cardiology 1, 2, 4, 5
For A3 (Severely Increased), strongly recommended to use ACE inhibitor or ARB therapy, target reduction of ≥30% in urinary albumin to slow CKD progression, and monitor serum creatinine and potassium closely, as recommended by the American Diabetes Association 1, 2

Optimize blood pressure control to reduce risk or slow progression of diabetic kidney disease, with targets individualized but generally <140/90 mmHg, as recommended by the American Diabetes Association and the European Society of Cardiology 1, 4
Optimize glucose control to reduce risk or slow progression of diabetic kidney disease, with HbA1c targets individualized based on patient factors, as recommended by the American Diabetes Association 1, 5
ACE inhibitors or ARBs are first-line therapy for albuminuria, and monitor for increased creatinine and hyperkalemia when starting RAS blockers, as recommended by the American Diabetes Association 1, 2, 4

At least annual assessment of urinary albumin and eGFR in patients with diabetes, and multiple specimens (2-3) collected within 3-6 months should be abnormal before confirming diagnosis, as recommended by the American Diabetes Association 1, 5
Refer to nephrology if eGFR <30 mL/min/1.73 m², uncertainty about etiology of kidney disease, difficult management issues, rapidly progressing kidney disease, or presence of nephrotic syndrome or active urinary sediment, as recommended by the American Diabetes Association 2, 5

Avoid using terms like "microalbuminuria" and "macroalbuminuria" as they are outdated, and be aware that spontaneous remission of moderately increased albuminuria can occur in up to 40% of patients with type 1 diabetes, as noted by the American Diabetes Association 1
Do not rely solely on dipstick tests for proteinuria as they may miss early albuminuria, as recommended by the European Society of Cardiology 4